The peptide gray market is already here. The FDA is just catching up.

The FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) for the 503A bulks list, potentially allowing compounding pharmacies to legally produce them. The vote reflects a shift toward regulated supply amid a booming gray market where Americans currently source peptides from China, with imports doubling to $328 million in 2025.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.